This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Qyuns Therapeutics’ US$1.07 billion licensing deal with Roche, Healthgen Biotech’s RMB 42 billion STAR Market IPO, and Immunofoco’s Series B+ funding for CAR-T therapies. Clinical updates include Bioheng’s CAR-T success in autoimmune diseases, Qyuns’ Phase III results for Crusekitug in ankylosing spondylitis, and OncoC4’s BTD for gotistobart in sqNSCLC. Additional highlights feature Hinova’s Phase I success for MASH, Zai Lab’s SCLC Phase 3 trial launch, and Hengrui’s KRAS G12D inhibitor moving to Phase III for pancreatic cancer.
